Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/8052
Title: Does spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction?
Authors: Vatankulu, M.A.
Bacaksiz, A.
Sonmez, O.
Alihanoglu, Y.
Koc, F.
Demir, K.
Gul, E.E.
Keywords: Aldosterone
Myocardial infarction
Preserved ejection fraction
Remodeling
Spironolactone
acetylsalicylic acid
bisoprolol
carvedilol
fosinopril
metoprolol
perindopril
ramipril
spironolactone
valsartan
acute heart infarction
adult
article
controlled study
echocardiography
female
follow up
gynecomastia
heart left ventricle ejection fraction
heart left ventricle enddiastolic volume
heart left ventricle endsystolic volume
heart left ventricle function
heart performance
heart ventricle remodeling
human
hyperkalemia
hypotension
major clinical study
male
priority journal
randomized controlled trial
ST segment elevation myocardial infarction
Adult
Aged
Analysis of Variance
Chi-Square Distribution
Dose-Response Relationship, Drug
Echocardiography, Doppler
Female
Humans
Male
Middle Aged
Mineralocorticoid Receptor Antagonists
Myocardial Contraction
Myocardial Infarction
Prospective Studies
Stroke Volume
Time Factors
Treatment Outcome
Turkey
Ventricular Function, Left
Ventricular Remodeling
Abstract: Aims: The aim of this study was to investigate the effects of spironolactone on left ventricular (LV) remodeling in patients with preserved LV function following acute myocardial infarction (AMI). Methods and Results: Successfully revascularized patients (n = 186) with acute ST elevation MI (STEMI) were included in the study. Patients were randomly divided into three groups, each of which was administered a different dose of spironolactone (12.5, 25 mg, or none). Echocardiography was performed within the first 3 days and at 6 months after MI. Echocardiography control was performed on 160 patients at a 6-month follow-up. The median left ventricular ejection fraction (LVEF) increased significantly in all groups, but no significant difference was observed between groups (P = 0.13). At the end of the sixth month, the myocardial performance index (MPI) had improved in each of the three groups, but no significant difference was found between groups (F = 2.00, P = 0.15). The mean LV peak systolic velocities (Sm) increased only in the control group during the follow-up period, but there is no significant difference between groups (F = 1.79, P = 0.18). The left ventricular end-systolic volume index (LVESVI) and the left ventricular end-diastolic volume index (LVEDVI) did not change significantly compared with the basal values between groups (F = 0.05, P = 0.81 and F = 1.03, P = 0.31, respectively). Conclusion: In conclusion, spironolactone dosages of up to 25 mg do not augment optimal medical treatment for LV remodeling in patients with preserved cardiac functions after AMI. © 2012 John Wiley & Sons Ltd.
URI: https://hdl.handle.net/11499/8052
https://doi.org/10.1111/1755-5922.12006
ISSN: 1755-5914
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
1755-5922.12006.pdf105.2 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

12
checked on Jun 29, 2024

WEB OF SCIENCETM
Citations

11
checked on Jul 17, 2024

Page view(s)

20
checked on May 27, 2024

Download(s)

20
checked on May 27, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.